BrightSpring Health Services, Inc. (NASDAQ:BTSG) saw a surge in revenue, adjusted EBITDA, and net income in Q3, prompting UBS to raise their price target to $42 and reiterate a Buy rating. The company’s strong performance was driven by growth in Pharmacy Solutions and Provider Services, with management raising revenue guidance for FY25.

BrightSpring Health Services, Inc. (NASDAQ:BTSG) is a post-acute care company providing a range of clinical services and pharmacy solutions across the US. With a focus on home and community-based care for medically complex and aging populations, the company has shown significant growth and potential for investment.

UBS analysts see potential in BTSG, but suggest that certain AI stocks may offer greater upside. For investors seeking undervalued AI opportunities, a free report on the best short-term AI stock is available. Explore other growth opportunities with stocks that are projected to double in 3 years and hidden AI stocks to consider. Disclosure: None.

Read more at Yahoo Finance: UBS Ups BrightSpring Target to $42, Reiterated Buy After Beat-and-Raise Q3